Have you heard the latest about gene therapy for hemophilia? Do you understand what genes are, how gene therapy works, and why it sparks such interest? Are you following the latest gene therapy clinical trial results, but have some questions about what it all means for individuals with hemophilia? The new WFH eLearning module Gene Therapy for Hemophilia explores all of these questions and more.
The Gene Therapy for Hemophilia module is an adaptation of the Global National Member Organization (NMO) Training 2018 plenary presentation by Glenn Pierce, WFH Vice President, Medical, and is part of the WFH Treatment Products eLearning Program designed for individual self-directed or small-group learning.
“Written for people with bleeding disorders and their carers and advocates, this comprehensive module is also an excellent foundational resource on gene therapy for any healthcare professional,” explains Glenn Pierce. As part of the Treatment Products eLearning Program, the module begins with a summary of some of the key concepts of modules 1 and 2: Introduction to Bleeding Disorders, and Evolution of Treatment Products. These two modules provide a thorough study of factor replacement therapies for bleeding disorders and reviewing them before embarking upon module 3 is highly recommended.
Gene therapy is an exciting therapeutic avenue that is currently being explored for a number of conditions, including hemophilia. Ongoing technical advances and developments in our understanding of how to deliver gene therapy and how the body responds to it are converging to make this the most promising moment in the history of gene therapy. Clinical trial results make headlines, but truly understanding what is happening in the field and what this may mean for individual people with hemophilia requires a deeper dive.